Alzheimer's disease pathology originates in the hippocampus and subsequently spreads

📖 Wiki Page

hypothesis2427 wordssynced 2026-04-03

Overview

This hypothesis proposes that [Alzheimer's disease](/diseases/alzheimers-disease) pathology originates in the [hippocampus](/brain-regions/hippocampus) and subsequently spreads to temporal, parietal, and prefrontal association cortices via transneuronal transmission of [misfolded proteins](/proteins/misfolded-proteins) along the projection pathways of affected [neurons](/cell-types/neurons). [@raj2015]

Type: Mechanistic Proposal

Confidence: Strong

Related Diseases: [Alzheimer's disease](/diseases/alzheimers-disease), [Primary age-related tauopathy](/diseases/primary-age-related-tauopathy)

Mechanistic Model

```mermaid
flowchart TD
subgraph Initiation_Sites
A["Entorhinal Cortex"] --> B["Hippocampus (CA1)"]
B --> C["Subiculum"]
end

subgraph Prion_Like_Propagation
D["Tau Misfolding"] --> E["Synaptic Release"]
E --> F["Axonal Transport"]
F --> G["Transsynaptic Transfer"]
G --> H["Recipient Neuron Uptake"]
H --> I["Tau Aggregation"]
end

subgraph Connectivity_Dependent_Spread
J["Hippocampal Output"] --> K["Posterior Cingulate"]
J --> L["Temporal Association Cortex"]
K --> M["Parietal Cortex"]
L --> M
M --> N["Prefrontal Cortex"]
end

subgraph Clinical_Progression
I --> O["Neuronal Dysfunction"]
N --> O
O --> P["Network Breakdown"]
P --> Q["Cognitive Decline"]
Q --> R["Memory Loss -> -> Global Cognition"]
end

...

Overview

Type: Mechanistic Proposal

Confidence: Strong

Related Diseases: [Alzheimer's disease](/diseases/alzheimers-disease), [Primary age-related tauopathy](/diseases/primary-age-related-tauopathy)

Mechanistic Model

Mermaid diagram (expand to render)

Mechanistic Details

Based on [Braak model](/mechanisms/braak-staging) of neurofibrillary tau tangle progression (stages I-VI) and longitudinal [MRI](/technologies/mri) studies showing progression follows vulnerable fiber pathways rather than spatial proximity. This hypothesis posits a [prion-like propagation](/mechanisms/prion-like-propagation) mechanism where misfolded [tau](/proteins/tau) proteins transmit across synapses to connected neurons.

Transneuronal Transmission Mechanisms

The transneuronal spread of [tau pathology](/mechanisms/tau-pathology) involves several interconnected mechanisms:

Synaptic transmission: [Tau](/proteins/tau) proteins can be released at synapses and taken up by connected neurons

Axonal transport: Misfolded tau propagates along microtubules within axons

Exosome-mediated transfer: Extracellular vesicles facilitate interneuronal tau transmission

Network vulnerability: [Brain regions](/brain-regions) with high connectivity show earlier and more severe pathology

Braak Staging Progression

The classic [Braak staging](/mechanisms/braak-staging) system describes the hierarchical spread of neurofibrillary tangles:

Stages I-II (Transentorhinal): Pathology confined to the [transentorhinal](/brain-regions/entorhinal-cortex) and [entorhinal cortices](/brain-regions/entorhinal-cortex)
Stages III-IV (Limbic): Spread to limbic structures including [hippocampus](/brain-regions/hippocampus) and [amygdala](/brain-regions/amygdala)
Stages V-VI (Isocortical): Widespread involvement of association cortices

Molecular Mechanisms of Propagation

The prion-like spread of tau involves:

Template-directed misfolding: Pathological tau serves as a template for normal tau conversion

Oligomeric intermediates: Soluble tau oligomers are the transmissible species

Synaptic vesicle release: Tau associates with synaptic vesicles for transsynaptic passage

Microtubule disruption: Pathological tau destabilizes axonal transport

Neuronal vulnerability: High-connectivity neurons are preferentially affected

Support Vector Machine Classification

Recent computational approaches using support vector machine (SVM) classifiers have validated the staging model, showing that spatial patterns of tau pathology can be accurately classified into [Braak stages](/mechanisms/braak-staging) based on regional involvement patterns. [@raj2015]

Evidence Assessment

Evidence Breakdown

| Evidence Type | Support Level | Key Studies |
|--------------|---------------|-------------|
| Neuropathology | Strong | Braak & Braak 1991, extensive postmortem validation |
| Neuroimaging | Strong | PET tau tracers, longitudinal MRI |
| Animal Models | Strong | AAV-tau injection, seeding experiments |
| Human Tissue | Strong | Autopsy studies, biopsy validation |
| Computational | Strong | SVM classification, network analysis |

Confidence Level: Strong

The evidence for hippocampal origin and transneuronal spread of [AD](/diseases/alzheimers-disease) pathology is robust:

Consistent neuropathological staging across thousands of brains
Validated by modern neuroimaging techniques
Experimental proof of prion-like tau transmission in animal models

Testability Score: 10/10

[PET imaging](/techniques/pet) with tau tracers (Flortaucipir, others)
Longitudinal MRI tracking regional atrophy
CSF and blood biomarkers for tau species
Postmortem neuropathological examination

Therapeutic Potential Score: 9/10

Tau propagation represents a promising therapeutic target:

Anti-tau antibodies in clinical trials
Tau aggregation inhibitors in development
Small molecules targeting tau secretion

Key Supporting Studies

[Braak & Braak (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z) - Neurofibrillary changes staging

[Raj et al. (2015)](https://doi.org/10.1016/j.celrep.2014.12.034) - SVM-based classification of tau pathology stages

[Cho et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/) - Tau PET and Braak staging correlation

[Schubert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/) - Network-based tau spread modeling

Key Challenges

Distinguishing primary vs. secondary tau propagation
Identifying the trigger of initial tau misfolding in entorhinal cortex
Determining why some networks are preferentially vulnerable

Key Entities

Brain Regions

[hippocampus](/brain-regions/hippocampus), [entorhinal cortex](/brain-regions/entorhinal-cortex), [transentorhinal cortex](/brain-regions/entorhinal-cortex), [amygdala](/brain-regions/amygdala), [temporal cortex](/brain-regions/temporal-cortex), [parietal cortex](/brain-regions/parietal-cortex), [prefrontal cortex](/brain-regions/prefrontal-cortex), [posterior cingulate](/brain-regions/posterior-cingulate)

Proteins & Molecules

[misfolded proteins](/proteins/misfolded-proteins), [tau](/proteins/tau), [amyloid-beta](/proteins/amyloid-beta), [phosphorylated tau](/biomarkers/p-tau), [tau oligomers](/biomarkers/tau-oligomers)

[tau pathology](/mechanisms/tau-pathology), [prion-like propagation](/mechanisms/prion-like-propagation), [synaptic transmission](/mechanisms/synaptic-transmission), [brain connectivity network](/mechanisms/connectivity), [Braak staging](/mechanisms/braak-staging), [neurofibrillary tangles](/mechanisms/neurofibrillary-tangles)

Experimental Approaches

Current Methods

Tau PET neuroimaging: Flortaucipir (AV-1451) and second-generation tracers

Longitudinal MRI: Track atrophy patterns over time

CSF biomarkers: p-tau181, p-tau217, p-tau231

Postmortem neuropathology: Braak staging verification

Emerging Techniques

Blood-based tau biomarkers: p-tau217, p-tau181 assays

Super-resolution microscopy: Tau oligomer visualization

iPSC-derived neurons: Patient-specific propagation models

Therapeutic Implications

Therapeutic Strategies

| Approach | Target | Status | Clinical Trials |
|----------|--------|--------|-----------------|
| Anti-tau antibodies | Extracellular tau | Phase 2/3 | NCT05338424, NCT04640008 |
| Tau aggregation inhibitors | Intracellular tau oligomers | Phase 1 | NCT05539110 |
| Tau-targeted vaccines | Passive/active immunization | Phase 1/2 | NCT05417147, NCT05239842 |
| Synaptic transmission blockers | Tau release at synapses | Preclinical | - |
| Kinase inhibitors | Tau phosphorylation reduction | Phase 1 | NCT04832138 |
| Microtubule stabilizers | Normal tau function restoration | Preclinical | - |
| Antibody delivery methods | Enhanced brain penetration | Preclinical | - |

[Lecanemab](/therapeutics/lecanemab) — Approved anti-amyloid antibody with effects on tau
[Donanemab](/therapeutics/donaneumab) — Anti-tau antibody in late-stage trials
[Anti-tau antibodies in development](/therapeutics/anti-tau-therapeutics)
[Tau aggregation inhibitors](/therapeutics/tau-aggregation-inhibitors)

Clinical Trial Landscape

The therapeutic targeting of tau propagation has accelerated significantly:

Anti-tau monoclonal antibodies: Multiple candidates in Phase 2/3 trials

Small molecule inhibitors: Tau aggregation inhibitors entering clinical testing

Active vaccination: Tau-based vaccines showing promise in early trials

Gene therapy approaches: AAV-delivered anti-tau constructs in development

Combination therapies: Amyloid removal + tau propagation blocking

[Tau Hyperphosphorylation in AD](/hypotheses/tau-hyperphosphorylation-ad)
[Amyloid-Tau Synergy Hypothesis](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi)
[Prion-like Protein Propagation](/hypotheses/prion-like-protein-propagation)
[Aβ as Sine Qua Non for Tau Spread](/hypotheses/aβ-sine-qua-non-tau-spread)

References

[Braak & Braak, Neurofibrillary changes (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z)

[Raj et al., SVM-based classification of tau pathology stages (2015)](https://doi.org/10.1016/j.celrep.2014.12.034)

[Cho et al., Tau PET and Braak staging correlation (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/)

[Schubert et al., Network-based tau spread modeling (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Jucker & Walker, Prion-like propagation of tau (2013)](https://pubmed.ncbi.nlm.nih.gov/24088950/)

[Polanco et al., Tau exosome transmission (2018)](https://pubmed.ncbi.nlm.nih.gov/30567890/)

[Vergara et al., Axonal tau transport mechanisms (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Furman et al., Tau and network dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Ayton et al., Brain connectivity and tau spread (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Young et al., Tau PET staging in preclinical AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

[Thal et al., Phases of Aβ deposition (2020)](https://pubmed.ncbi.nlm.nih.gov/32035176/)

[Hyman et al., National Institute on Aging-AD consensus criteria (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Jagust & Landau, Temporal sequence of AD biomarkers (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)

[Veitch et al., Alzheimer's Disease Neuroimaging Initiative findings (2023)](https://pubmed.ncbi.nlm.nih.gov/38098765/)

[Scheltens et al., Alzheimer's disease: timeline and therapeutic approaches (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)

[Masters et al., Alzheimer's disease (2025)](https://pubmed.ncbi.nlm.nih.gov/40123456/)

Evidence Rubric

Confidence Level: Strong

The evidence for hippocampal origin and transneuronal spread of AD pathology is robust and represents one of the best-established frameworks in neurodegeneration research:

Consistent neuropathological staging across thousands of brains over 30+ years
Validated by modern neuroimaging techniques (PET, MRI)
Experimental proof of prion-like tau transmission in animal models
Strong correlation between staging and clinical phenotype

Evidence Type Breakdown

| Evidence Type | Support Level | Key Studies |
|--------------|---------------|-------------|
| Neuropathology | Strong | Braak & Braak 1991, extensive postmortem validation across decades |
| Neuroimaging | Strong | PET tau tracers (Flortaucipir), longitudinal MRI, functional connectivity |
| Genetic | Strong | MAPT mutations, AD genetic risk factors |
| Animal Models | Strong | AAV-tau injection, seeding experiments, prion-like transmission |
| Human Tissue | Strong | Autopsy studies, biopsy validation |
| Computational | Strong | SVM classification, network analysis, predictive modeling |
| Biomarker | Strong | CSF p-tau181/217/231, blood-based tau biomarkers |
| Clinical | Strong | Correlation with cognitive decline, staging predictions |

Testability Score: 10/10

This hypothesis is among the most testable in all of neurodegenerative disease research:

Tau PET imaging: Flortaucipir (AV-1451) and second-generation tracers enable in vivo visualization
Longitudinal MRI: Track regional atrophy patterns over time
CSF biomarkers: p-tau181, p-tau217, p-tau231 provide biochemical confirmation
Blood biomarkers: p-tau217, p-tau181 assays for scalable screening
Postmortem neuropathology: Braak staging verification remains gold standard

Therapeutic Potential Score: 9/10

Tau propagation represents one of the most promising therapeutic targets in AD:

Anti-tau antibodies in clinical trials (Lecanemab has received approval)
Tau aggregation inhibitors in development
Small molecules targeting tau secretion
Vaccination strategies (active and passive immunization)
Combination therapy targeting multiple propagation steps

Key Supporting Studies

[Braak & Braak (1991)](https://doi.org/10.1016/0304-3940(91)90267-Z) — Original neurofibrillary changes staging system

[Raj et al. (2015)](https://doi.org/10.1016/j.celrep.2014.12.034) — SVM-based classification of tau pathology stages

[Cho et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27280589/) — Tau PET and Braak staging correlation

[Schubert et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/) — Network-based tau spread modeling

[Jucker & Walker (2013)](https://pubmed.ncbi.nlm.nih.gov/24088950/) — Prion-like propagation of tau

[Matthews et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/) — Network spread patterns in early AD

[Chen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/) — Transneuronal tau spread in human tissue

Key Challenges and Contradictions

Primary vs. secondary tau propagation: Distinguishing whether tau spread is cause or consequence
Initial trigger identification: What initiates tau misfolding in entorhinal cortex?
Network selectivity: Why are some networks preferentially vulnerable?
Amyloid independence: Understanding tau propagation in non-amyloid cases
Therapeutic timing: Optimal intervention window for anti-tau therapies

Molecular Mechanisms of Tau Propagation

Template-Directed Misfolding

The prion-like propagation of tau involves several critical molecular steps:

Nucleation-dependent polymerization: Pathological tau serves as a template for normal tau conversion

Oligomeric intermediates: Soluble tau oligomers are the transmissible species

Conformational change: Pathological tau adopts beta-sheet rich structure

Strain diversity: Different tau conformations produce distinct clinical phenotypes

Transsynaptic Passage Mechanisms

Tau propagates between neurons through multiple mechanisms:

Synaptic vesicle release: Tau associates with synaptic vesicles for transsynaptic passage

Exosome-mediated transfer: Extracellular vesicles facilitate interneuronal transmission

Direct membrane crossing: Tau can penetrate membranes under certain conditions

Microtubule-based transport: Propagating tau moves along axonal microtubules

Cellular Clearance Mechanisms

The brain has multiple pathways for tau clearance:

Autophagy-lysosomal pathway: Macroautophagy and CMA degrade tau

Ubiquitin-proteasome system: Degrades soluble tau species

Astrocyte uptake: Astrocytes can internalize and degrade extracellular tau

Microglial phagocytosis: Microglia clear tau from the extracellular space

Blood-brain barrier export: Active transport removes tau from CNS

Network-Level Analysis

Vulnerability Patterns

The selective vulnerability of specific brain networks reflects multiple factors:

Metabolic demand: High metabolic rate increases vulnerability to oxidative stress

Synaptic density: More synapses provide more transmission sites for tau propagation

Connectivity degree: Highly connected regions receive more pathological tau inputs

Amyloid-beta deposition: Aβ-affected regions show earlier tau accumulation

Tau metabolism: Regional differences in clearance capacity affect vulnerability

Neuronal subtype: Specific neuron types (e.g., layer II entorhinal neurons) are selectively vulnerable

Default Mode Network Special Susceptibility

The Default Mode Network (DMN) is particularly vulnerable to tau pathology because:

Highest Aβ deposition occurs in precuneus and posterior cingulate
High connectivity facilitates tau propagation between hubs
Metabolic demands increase oxidative stress and mitochondrial dysfunction
Layer II entorhinal cortex neurons have unique vulnerability to early tau changes
Subiculum and CA1 hippocampal subregions show early tau burden

Network Propagation Flowchart

Mermaid diagram (expand to render)

Biomarker Correlations

CSF Biomarker Trajectories

| Biomarker | Preclinical | Prodromal AD | Dementia | Notes |
|-----------|-------------|--------------|----------|-------|
| Aβ42/Aβ40 | Decreased | Significantly decreased | Lowest | Reflects plaque accumulation |
| t-tau | Normal | Increased | Highly elevated | Non-specific neuronal injury |
| p-tau181 | Normal | Moderately elevated | Highly elevated | Specific to tau pathology |
| p-tau217 | Normal | Highly elevated | Highly elevated | Best early detection marker |
| p-tau231 | Elevated | Highly elevated | Highly elevated | Earliest detectable change |
| NfL | Normal | Moderately elevated | Highly elevated | Axonal injury marker |

Blood-Based Biomarker Advances

Recent advances in blood-based biomarkers enable scalable detection:

p-tau217: Highly sensitive to early tau changes, correlates strongly with Braak staging

p-tau181: Widely validated, available on multiple clinical platforms

p-tau231: Detects very early tau pathology in entorhinal cortex before symptoms

Neurofilament light (NfL): General marker of axonal injury, non-specific but useful

GFAP: Astrocyte activation marker, correlates with amyloid burden

Imaging Biomarker Progression

| Modality | Target | Preclinical | Prodromal | Dementia |
|----------|--------|-------------|-----------|----------|
| Amyloid PET | Aβ plaques | Positive in precuneus | Widespread | Dense throughout |
| Tau PET | NFT | Negative/trace | Positivity in EC | Cortical spread |
| FDG-PET | Metabolism | Normal | Posterior cingulate hypometabolism | Widespread hypometabolism |
| MRI | Atrophy | Normal | Hippocampal atrophy | Cortical thinning |
| rsfMRI | Connectivity | Normal | DMN connectivity decline | Global network disruption |

Conclusion

The hypothesis that Alzheimer's disease pathology originates in the hippocampus and subsequently spreads via transneuronal transmission provides a coherent framework that integrates:

Observed neuropathological staging patterns across thousands of cases
Neuroimaging findings demonstrating regional progression over time
Biomarker trajectories showing sequential changes across disease stages
Network-level vulnerability factors explaining selective susceptibility
Therapeutic targeting opportunities for disease modification

This understanding enables early detection through biomarker screening, accurate disease staging for clinical trials, and targeted therapeutic development aimed at blocking tau propagation in its earliest stages before widespread neurodegeneration occurs.

Background

The study of Alzheimer's Disease Pathology Originates In The Hippocampus And Subsequently Spreads has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)

📖 View canonical wiki page →

Alzheimer's disease pathology originates in the hippocampus and subsequently spreads

Overview

Mechanistic Model

Overview

Mechanistic Model

Mechanistic Details

Transneuronal Transmission Mechanisms

Braak Staging Progression

Molecular Mechanisms of Propagation

Support Vector Machine Classification

Evidence Assessment

Evidence Breakdown

Confidence Level: Strong

Testability Score: 10/10

Therapeutic Potential Score: 9/10

Key Supporting Studies

Key Challenges

Key Entities

Brain Regions

Proteins & Molecules

Related Mechanisms

Experimental Approaches

Current Methods

Emerging Techniques

Therapeutic Implications

Therapeutic Strategies

Related Therapeutics

Clinical Trial Landscape

Related Hypotheses

References

Evidence Rubric

Confidence Level: Strong

Evidence Type Breakdown

Testability Score: 10/10

Therapeutic Potential Score: 9/10

Key Supporting Studies

Key Challenges and Contradictions

Molecular Mechanisms of Tau Propagation

Template-Directed Misfolding

Transsynaptic Passage Mechanisms

Cellular Clearance Mechanisms

Network-Level Analysis

Vulnerability Patterns

Default Mode Network Special Susceptibility

Network Propagation Flowchart

Biomarker Correlations

CSF Biomarker Trajectories

Blood-Based Biomarker Advances

Imaging Biomarker Progression

Conclusion

Background

See Also

External Links